Cardiology

Hispanic and Latino adults have a high prevalence of cardiovascular risk factors, but many are receiving inadequate treatment.

The American Heart Association published a special issue to discuss current research in cardiovascular disease and outcomes in women.

Investigators used MRI scans of the heart to identify whether heart injury was caused by COVID-19 infection.

New clinical practice guidelines call for lowering blood pressure levels down to 120 mmHg systolic for those with chronic kidney disease.

Once-weekly semaglutide 2.4 mg resulted in sustained reductions in weight for those who are overweight or obese, the investigators reported.

Novartis’ sacubitril/valsartan (Entresto) is now indicated for use in the treatment of chronic heart failure.

The American Heart Association’s recent scientific statement found that mental health impacts risk factors for heart disease.

Insulin resistance and type 2 diabetes were major contributors to premature coronary heart disease, according to the study results.

The American Heart Association (AHA) is urging those with heart conditions and those who are at risk for cardiovascular disease to receive the COVID-19 vaccine.

Pharmacists can help patients through education, therapy, and lifestyle modifications.

The latest Heart Disease and Stroke Statistical Update highlighted pandemic-related trends that may impact cardiovascular disease mortality for years.

A recent study examined patient characteristics and factors affecting COVID-19 mortality in individuals with diabetes.

Investigators compared outcomes among patients with COVID-19 and hypertension through modifying blood pressure medication use.

The FDA has approved vericiguat (Verquvo; Merck) for use in patients with chronic heart failure (HF) and ejection fraction less than 45%.

High blood pressure appears to accelerate a decline in cognitive performance in middle-aged and older adults, according to new research.

Results of a recent study showed that both high and low density lipoprotein cholesterol were linked to an increase risk of all-cause mortality in the general population.

The agency granted priority review to dapagliflozin (Farxiga; AstraZeneca) for the treatment of new or worsening chronic kidney disease in adults with and without type 2 diabetes.

Investigators evaluated pharmacogenetic results for statin myopathy risk to determine the clinical benefit of these testing programs.

An FDA panel voted to recommend the expanded use of sacubitril/valsartan (Entresto; Novartis).

Increased prevalence of high blood pressure may be among the “collateral damage” from isolation as a result of the COVID-19 pandemic, investigators said.

“This first-generation polypill is not magic, but it would be clinically worthwhile.”

Of the nearly 3 million Americans included in the study, just 1.4% had the flu vaccine and 1.4% had the pneumonia vaccine.

The meta-analysis accrued data from 18 studies that focused on patients with hospitalized and chronic heart failure.

A key opinion leader discusses the most significant unmet needs in the evolving spectrum of cardiovascular risk management.

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

A study compared cardiac events associated with azithromycin versus amoxicillin.

The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.